Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2016) 43 OC4 | DOI: 10.1530/endoabs.43.OC4

WCTD2016 Abstract Topics Cardiovascular Outcome Studies (12 abstracts)

Antihyperglycermic drugs use and new-onset atrial fibrillation in elderly patients: a popuation-based longitudinal cohort study

Gwo-Ping Jong 1 , Yi-Sheng Liou 2 , Tsochiang Ma 3 & Hung-Yi Chen 4


1Division of Internal Cardiology, Chung Shan Medical University Hospital and Chung Shan Medical University, Taichung City, Taiwan; 2Department of Family Medicine and Geriatrics, Taichung Veteran General Hospital, Taichung City, Taiwan; 3Department of Health Management, China Medical University, Taichung City, Taiwan; 4Institute of Pharmacy, China Medical University, Taichung City, Taiwan.

Background: Antihyperglycermic drugs have been linked to new-onset atrial fibrillation (NAF); however, the effect of different class antihyperglycermic drugs on the development of NAF in elderly patients with diabetes millitus (DM) has not been well studied.

Objectives: We investigated the association between different class antihyperglycermic drugs and NAF in elderly patients.

Methods: This was a retrospective cohort study performed using database of National Health Insurance Program in Taiwan from January 2000 to December 2011. Prescriptions for antihyperglycermic drug before the index date were retrieved from a prescription database. A total of 1931 participants aged 65 and older who were newly diagnosed with atrial fibrillation from 2005 to 2011 were assigned to the NAF group, whereas 7724 sex-matched, age-matched, diabetes duration-matched, and propensity score-matched randomly selected participants without NAF served as the non-NAF group.The multivariable logistic regression modle was used to estimate the odds ratios (ORs) and 95% confence interval (CI) of NAF associated with different class antihyperglycermic agent use. Non-users served as the reference group.

Results: The overall risk of NAF was netural effect (OR, 0.93; 95% CI, 0.83–1.04) between NAF and non-NAF group. The risk of NAF after adjusting for sex, age, comorbilities, and concurrent medication was higher among users of insulins (OR, 1.58; 95% CI, 1.37–1.82) than among non-users. Patients who took dipeptidyl peptidase four inhibitors (OR, 0.65; 95% CI, 0.45–0.93) was at lower risk of developing NAF than non-users. Metformins, acarboses, glinides, sulfonylureas and thiazolidinediones were not associated with risk of NAF.

Conclusion: In this population, dipeptidyl peptidase four inhibitors are at lower risk of NAF. Insulins was associated with a significant increase in the risk of NAF during long-term follow-up.

Article tools

My recent searches

No recent searches.